消息面上，近日，先声药业发布公告，内容有关集团附属公司已与AbbVie Inc. 附属公司就研究性新候 选药物SIM0500订立海外许可选择权协议。根据该协议条款，集团将从AbbVie收取首付款，以及最高可 达10.55亿美元的选择性权益及里程碑付款，同时双方约定就净销售额收取分级特许权使用费。 智通财经APP获悉，先声药业(02096)涨超3%，截至发稿，涨2.69%，报12.61港元，成交额2201.87万港 元。 华泰证券指出，先声药业核心产品SIM0500获得艾伯维4000万美元里程碑付款，该 BCMA/GPRC5D/CD3三抗TCE已获FDA快速通道认定，预计年内读出I期临床数据并实现概念验证。该 行认为，公司创新研发体系与平台技术能力持续获得验证，已达成多项10亿美元级海外授权合作。 SIM0500在临床前研究中显示出显著优于双抗TCE的抗肿瘤活性，同靶点组合竞品中全球进度领先。 ...

华泰证券指出，先声药业核心产品SIM0500获得艾伯维4000万美元里程碑付款，该 BCMA/GPRC5D/CD3三抗TCE已获FDA快速通道认定，预计年内读出I期临床数据并实现概念验证。该 行认为，公司创新研发体系与平台技术能力持续获得验证，已达成多项10亿美元级海外授权合作。 SIM0500在临床前研究中显示出显著优于双抗TCE的抗肿瘤活性，同靶点组合竞品中全球进度领先。 先声药业(02096)涨超3%，截至发稿，涨2.69%，报12.61港元，成交额2201.87万港元。 消息面上，近日，先声药业发布公告，内容有关集团附属公司已与AbbVie Inc.附属公司就研究性新候选 药物SIM0500订立海外许可选择权协议。根据该协议条款，集团将从AbbVie收取首付款，以及最高可达 10.55亿美元的选择性权益及里程碑付款，同时双方约定就净销售额收取分级特许权使用费。 ...

根据披露，SIM0500是一款人源化GPRC5D-BCMA-CD3三特异性抗体，由集团通过其专有的T细胞衔接 器多特异性抗体技术平台开发。该分子结合了低亲和力而高靶向启动的CD3抗体，以及抗G蛋白偶联受 体C家族5组成员D(GPRC5D)和抗B细胞成熟抗原(BCMA)的两种抗肿瘤相关抗体。SIM0500通过多种抗 肿瘤机制，表现出了针对MM细胞的强大T细胞毒性效应。 格隆汇2月3日丨先声药业(02096.HK)发布公告，集团附属公司已与AbbVie Inc.("AbbVie")附属公司就研 究性新候选药物SIM0500订立海外许可选择权协议。根据该协议条款，集团将从AbbVie收取首付款，以 及最高可达10.55亿美元的选择性权益及里程碑付款，同时双方约定就净销售额收取分级特许权使用 费。继此前已收到该协议项下首付款后，集团已于近期进一步收到来自AbbVie支付的4,000万美元款 项。该款项的支付，体现了集团与AbbVie围绕推进SIM0500临床开发合作的积极进展。 ...

先声药业(02096)发布公告，内容有关集团附属公司已与AbbVie Inc.附属公司就研究性新候选药物 SIM0500订立海外许可选择权协议。根据该协议条款，集团将从AbbVie收取首付款，以及最高可达 10.55亿美元的选择性权益及里程碑付款，同时双方约定就净销售额收取分级特许权使用费。公司董事 会欣然宣布，继此前已收到该协议项下首付款后，集团已于近期进一步收到来自AbbVie支付的4000万 美元款项。该款项的支付，体现了集团与AbbVie围绕推进SIM0500临床开发合作的积极进展。 SIM0500是一款人源化GPRC5D-BCMA-CD3三特异性抗体，由集团通过其专有的T细胞衔接器多特异性 抗体技术平台开发。该分子结合了低亲和力而高靶向启动的CD3抗体，以及抗G蛋白偶联受体C家族5组 成员D(GPRC5D)和抗B细胞成熟抗原(BCMA)的两种抗肿瘤相关抗体。SIM0500通过多种抗肿瘤机制， 表现出了针对MM细胞的强大T细胞毒性效应。 ...

智通财经APP讯，先声药业(02096)发布公告，内容有关集团附属公司已与AbbVie Inc. 附属公司就研究 性新候选药物SIM0500订立海外许可选择权协议。根据该协议条款，集团将从AbbVie收取首付款，以及 最高可达10.55亿美元的选择性权益及里程碑付款，同时双方约定就净销售额收取分级特许权使用费。 公司董事会欣然宣布，继此前已收到该协议项下首付款后，集团已于近期进一步收到来自AbbVie支付 的4000万美元款项。该款项的支付，体现了集团与AbbVie围绕推进SIM0500临床开发合作的积极进展。 SIM0500是一款人源化GPRC5D-BCMA-CD3三特异性抗体，由集团通过其专有的T细胞衔接器多特异性 抗体技术平台开发。该分子结合了低亲和力而高靶向启动的CD3抗体，以及抗G蛋白偶联受体C家族5组 成员D(GPRC5D)和抗B细胞成熟抗原(BCMA)的两种抗肿瘤相关抗体。SIM0500通过多种抗肿瘤机制， 表现出了针对MM细胞的强大T细胞毒性效应。 ...

Simcere Pharmaceutical Group Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 先聲藥業集團有限公司 （於香港註冊成立的有限公司） （股份代號：2096） 自願公告 收到與AbbVie就SIM0500海外許可選擇權協議 的近期里程碑付款 本公告由先聲藥業集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）自 願作出，以告知本公司股東及潛在投資者本集團最新業務更新。 –1– 關於SIM0500 SIM0500是一款人源化GPRC5D-BCMA-CD3三特異性抗體，由本集團通過其專有 的T細胞銜接器多特異性抗體技術平臺開發。該分子結合了低親和力而高靶向啟動 的CD3抗體，以及抗G蛋白偶聯受體C家族5組成員D(GPRC5D)和抗B細胞成熟抗 原(BCMA)的兩種抗腫瘤相關抗體。SIM0500通過多種抗腫瘤機制，表現出了針對 MM細胞的強大T細胞毒性效應。 關於本集團 本公司是一家創新與研發驅動的製藥公司，且本集 ...

Core Insights - Mesoblast Limited has appointed James M. O'Brien as the new Chief Financial Officer (CFO) to support its transition to a fully integrated commercial organization [1][2] - The company aims to enhance its financial leadership as it commercializes its product Ryoncil® and seeks label expansion [2] Company Overview - Mesoblast is a global leader in developing allogeneic cellular medicines for severe inflammatory diseases, utilizing proprietary mesenchymal lineage cell therapy technology [3] - The company has a strong intellectual property portfolio with over 1,000 patents or applications, providing commercial protection until at least 2044 in major markets [6] Product Information - Ryoncil® is the first FDA-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged 2 months and older [4] - Mesoblast is developing additional therapies for various inflammatory diseases and conditions, including heart failure and chronic low back pain [5] Financial Leadership - James M. O'Brien brings extensive experience in financial management from previous roles at Actavis plc, Cognition Therapeutics, Inc., and Faron Pharmaceuticals, among others [2] - His expertise includes overseeing corporate finance, reporting, internal controls, and accounting operations, with a history of managing transactions totaling nearly $10 billion [2]

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to serve as lead plaintiff is June 3, 2025, which requires a motion to the Court [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has a history of significant settlements, including over $438 million recovered for investors in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders made false and misleading statements related to a secondary stock offering on October 16, 2023 [5]. - The secondary offering was purportedly designed to allow Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement, which was made just 51 days later at $45 per share, nearly double the offering price [5].

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made false statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering allowed Bain Capital to acquire shares at a discounted price before AbbVie Inc.'s acquisition announcement, which was made just 51 days later at $45 per share, nearly double the offering price [5]. - Bain Capital's discounted purchases from the offering resulted in a windfall of over $120 million when the true details were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, highlighting their expertise in this area [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering, which may have artificially deflated the stock price prior to a merger announcement with AbbVie Inc. [1][2] Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, leading to an artificial deflation of Cerevel's stock price [2] - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at this artificially depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2] - The January 18, 2024 Proxy statement from Cerevel is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [2] Group 2: Class Action Details - The class period for the lawsuit includes shareholders who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1] - The deadline for shareholders to register for the class action and seek lead plaintiff status is June 3, 2025, with no cost or obligation to participate [3] - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status [3]